Homology Medicines Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments
March 12, 2020 16:10 ET
|
Homology Medicines, Inc.
- Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently Controlled Expansion Part Mid-Year 2020 - -...
Homology Medicines to Participate in Upcoming Investor and Scientific Conferences
February 20, 2020 09:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following investor and...
Homology Medicines Presents New Data Characterizing AAVHSCs as Potential Gene Therapies for Nervous System Disorders
February 13, 2020 09:00 ET
|
Homology Medicines, Inc.
- Data Demonstrate AAVHSCs Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier, Produced Normal Levels of Human Protein and Reduced Key Biochemical Markers of Disease in Preclinical Models - ...
Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU
December 17, 2019 16:01 ET
|
Homology Medicines, Inc.
- Well-Tolerated in First-in-Human AAVHSC Gene Therapy Trial - - Preliminary Data from First Patient in Second Cohort Showed Dose-Response with Observed Reductions from Baseline in Phe and Phe/Tyr...
Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care
December 16, 2019 09:00 ET
|
Homology Medicines, Inc.
These Data Highlight Unmet Medical Need for Therapies to Control Phe Concentrations by Targeting the Underlying Cause of PKU BEDFORD, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Homology Medicines,...
Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer
December 03, 2019 08:30 ET
|
Homology Medicines, Inc.
- Experienced Clinical Geneticist with Track Record in Rare Disease Drug Development Joins Homology’s Senior Management - BEDFORD, Mass., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc....
Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs
November 26, 2019 15:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its proprietary...
Homology Medicines Reports Third Quarter 2019 Financial Results and Recent Highlights
November 12, 2019 16:09 ET
|
Homology Medicines, Inc.
Expects to Report Initial Clinical Data from Phase 1/2 pheNIX PKU Gene Therapy Clinical Trial by Year-End Presented Preclinical Data Demonstrating Progress in MLD Gene Therapy and PKU Gene Editing...
Homology Medicines Presents Preclinical Data From Its Investigational PKU Gene Editing Program, Demonstrating Phenotypic Correction and Molecular Confirmation of Editing Precision
October 25, 2019 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the oral presentation of preclinical data related to its...
Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies
October 21, 2019 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that support its...